Skip to main content

Table 2 Clinical and PET characteristics of different PTCL subtypes

From: Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL)

Characteristics PTCL-NOS AITL ALCL (ALK)
Sex: female/male 18/29 9/21 3/4
Age: ≤ 60 years/> 60 years 25/22 12/18 6/1
LDH: normal/higher than normal 26/21 9/21 3/4
B symptoms: no/yes 21/26 8/22 4/3
ECOG performance status: 0–1/> 1 29/18 21/9 7/0
Ann Arbor stage: I–II/III–IV 10/37 2/28 3/4
Extranodal sites ≥ 2: no/yes 33/14 25/5 7/0
BMB: negative/positive 35/12 22/8 6/1
Ki-67 ≥ 80%: no/yes 35/12 22/8 6/1
Platelet cell count ≥ 150 × 109/L: no/yes 24/23 22/8 2/5
SUVmax 10.6 (2.6–25.5) 11.3 (3.9–25.5) 14.3 (4.3–33.5)
TMTV (cm3) 277.7 (3.4–1334.6) 521.5 (4.3–1887.0) 67.8 (3.8–250.0)
TLG 638.1 (10.9–3255.9) 1825.5 (10.9–6308.0) 411.1 (14.9–1182.9)
  1. PTCL-NOS peripheral T-cell lymphoma (PTCL) not otherwise specified, AITL angioimmunoblastic T-cell lymphoma, ALCL anaplastic large-cell lymphoma, LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, BMB bone marrow biopsy